Test Price
2,800 AED✅ Home Collection Available
SDHD Gene Mitochondrial Complex II Deficiency NGS Genetic Analysis in UAE | AED 2800 | DHA-Compliant
Executive Summary & Core Metrics
Executive Summary: This ISO 9001:2015‑certified NGS test (LOINC 21642‑3) delivers 99.9% diagnostic sensitivity for SDHD variants causing mitochondrial complex II deficiency and hereditary paraganglioma‑pheochromocytoma syndrome. Testing is performed under strict DHA oversight at DNA Labs UAE, with post-result telephonic clinical guidance from a consultant medical geneticist.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance from Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced Next‑Generation Sequencing (NGS) test examines the entire coding region of the SDHD gene to identify pathogenic variants associated with mitochondrial complex II deficiency — a severe neurometabolic disorder — and hereditary paraganglioma‑pheochromocytoma syndrome. Ordered primarily by Neurologists, Oncologists, and Medical Geneticists, it provides unambiguous genotype‑phenotype correlation for precision management.
| Feature | Our SDHD NGS Test | Closest Alternative |
|---|---|---|
| Precision | Full Gene Sequencing with CNV calling | Targeted mutation panels only |
| Methodology | NGS (Illumina® platform, 300x coverage) | Sanger sequencing (limited to known hotspots) |
| Turnaround Time | 3–4 Weeks with expedited reporting | 4–6 Weeks |
| Clinical Utility | Covers all exons ±20 bp flanking; ACMG classification | May miss rare non‑exonic mutations |
| UAE Compliance | DHA/MOHAP‑approved, ISO 9001:2015 | Often lacks local accreditation |
Physician Insight & Safety Protocols
“A confirmed pathogenic SDHD variant indicates a hereditary predisposition that necessitates lifelong surveillance for paraganglioma and pheochromocytoma. A negative result does not exclude other mitochondrial or tumour syndromes. I strongly advise all patients to review findings with a clinical geneticist and to never alter prescribed medications without prior consultation.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Safety Advisory: Medication & Clinical Caution
⚠ Medication Warning
Do not discontinue or alter any prescribed medication without consulting your treating physician. Abrupt cessation of certain therapies can lead to serious adverse events. Always consult a specialist before making changes.
Health Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Inability to provide informed consent.
- Active anticoagulation therapy without medical clearance for venipuncture.
- Known mosaicism requiring skin biopsy (consult with geneticist).
Emergency Red Flags
- New‑onset severe headaches, palpitations, or unexplained hypertension – seek urgent endocrinology evaluation.
- In infants: suspected mitochondrial crisis (lactic acidosis, seizures) requires immediate emergency care.
- For minors: testing requires guardian consent and a referral from a paediatric neurologist or medical geneticist, in full compliance with UAE law.
Patient FAQ & Clinical Guidance
1. What does this SDHD genetic test detect?
This NGS test identifies pathogenic variants in the SDHD gene that cause mitochondrial complex II deficiency and hereditary paraganglioma‑pheochromocytoma syndrome with >99% accuracy. The analysis covers the entire coding sequence, splice sites, and copy number variations, providing a definitive molecular diagnosis for at‑risk individuals.
2. How is the sample collected and what is the turnaround time?
Sample collection is performed via a standard blood draw (EDTA tube) or dried blood spot (FTA card) by a trained phlebotomist. VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection is available daily from 8 AM to 11 PM. Results are typically reported within 3–4 weeks from sample receipt.
3. Is this test covered by insurance in the UAE?
Most UAE insurers cover SDHD genetic testing when deemed medically necessary. We verify your coverage instantly via WhatsApp (+971 54 548 8731) before scheduling. Direct billing and pre‑approval documentation assistance are provided. All genetic results are handled with strict data privacy per UAE PDPL.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License 1143 and adheres fully to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for handling genetic data. All clinical testing follows Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient safety and informed consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | SDHD Gene Mitochondrial Complex II Deficiency NGS Genetic Analysis |
| Price (AED) | 2800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA (≥1 µg), or dried blood spot (FTA card) |
| Methodology Used | Next-Generation Sequencing (Illumina® platform, 300x coverage) with CNV calling |
| ICD-10-CM Code | E88.39, D44.1 |
| LOINC Code | 21642-3 |
| DHA Facility License & Laboratory Address Invariants | DHA License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians